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ABSTRACT
Objectives: To obtain quality-adjusted life-years, different respondent
groups, such as patients or the general public, may be asked to value health
states. Until now, it remains unclear if the respondent group has an
inﬂuence on the values obtained. We assessed this issue through meta-
analysis.
Methods: A literature search was performed for studies reporting valua-
tions given by patients and nonpatients. Studies using indirect utility
instruments were excluded.
Results: From 30 eligible studies, 40 estimators were retrieved revealing a
difference between respondent group (Cohen’s d = 0.20, P < 0.01). When
elicitation methods were analyzed separately, patients gave higher
valuations than nonpatients using the time trade-off (TTO) (N = 25,
unstandardized d = 0.05, P < 0.05) and the visual analog scale (VAS)
(N = 22, unstandardized d = 0.04, P < 0.05). When the standard gamble
was used, no difference was seen (N = 24, unstandardized d = 0.01,
P = 0.70).
Conclusion: In contrast with Dolders et al., our results show that patients
give higher valuations than members of the general public. For future
cost-utility analyses, researchers should be aware of the differential effects
of respondent group for the elicitation methods TTO and VAS.
Keywords: general population, health status, meta-analysis, patient pref-
erences, utility assessment.
Introduction
Valuations used in decision analyses and cost-utility analyses can
be given by different groups, such as patients or the general public.
Three studies have investigated the effect of response group by
summing results of empirical studies [1–3]. Two of these studies, a
review, and a meta-analysis of prostate cancer utilities, found
higher valuations given by patients. The third, a meta-analysis on
varying patient groups, did not ﬁnd any difference. The latter two
included indirect utility instruments like the European Quality of
Life Five Dimensions (EQ-5D)-tariff [4] or Health Utilities Index
Mark (HUI) [5] and includedmultiple health state valuations from
the same study sample. In studies using indirect utility instru-
ments, only patients are approached to participate, members of
the public are not included as a separate sample. Such studies
calculate health state utilities of members of the general public
frompatients’ answers to a short questionnaire. These answers are
put in a model captured from an earlier study [4] which generates
the utility values of the general public. Therefore, including more
than one study using indirect utility instruments leads to multiple
health state valuations from the same subject sample, which is a
violation of the assumption of independent data points. This may
have led to a distortion of the standard error, an inﬂated sample
size, and an overrepresentation of certain studies [6]. The aim of
our studywas to investigate throughmeta-analysis the inﬂuence of
the respondent group on valuations avoiding this bias.
Methods
Search and Retrieval of Studies
Studies reporting valuations given by patients and by members of
the general public, professionals, or proxies (which we from now
on refer to as “nonpatients”) were retrieved through the com-
puterized databases PsychInfo and PubMed. Studies published
between 1970 and October 2008 were searched using prefer-
ences, utility, patient, public and, respectively, time trade-off
(TTO), standard gamble (SG), or visual analog scale (VAS) as key
words. With the so-called snowball method, the bibliographic
information of De Wit et al. [1], Dolders et al. [2], Bremner et al.
[3], and other retrieved studies were searched for additional
studies. With the database Web of Science, we retrieved studies
for the citations of the already retrieved studies.
Abstracts were examined regarding the inclusion criteria.
Studies were included if they reported valuations of both patients
and nonpatients, used a standard utility method (TTO, SG, or
VAS), included participants 18 years, and were written in
English. Studies that used indirect instruments (classiﬁcation
systems), that investigated mental health states, or in which
nonpatients answered what they thought the patient would have
answered, were excluded.
Data Extraction
A detailed coding system was used to extract data. From each
study, the mean valuations and SDs for each evaluated health
state were coded for every group. If these data were not reported,
authors were contacted. We excluded studies when the authors
did not respond after three attempts or could not reveal the mean
valuations. If only the SDs were missing, we estimated these by
the weighted sum of the SDs reported in the included studies. We
further coded: elicitation method, nature of the nonpatient
respondent group, and various types of information about the
health state description used. More information about the coding
system can be found in Appendix A at: http://www.ispor.org/
Publications/value/ViHsupplementary/ViH13i2_Peeters.asp.
Information of the retrieved studies was independently rated
by two judges (A.M.S. and Y.P.) with satisfactory agreement for
most variables (Cohen’s Kappa between 1 and 0.77). Agreement
on the variable “own health state or hypothetical health state”
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was low, (Cohen’s Kappa = 0.61) in three of 30 ratings the judges
disagreed. All dissimilar ratings were compared and discussed
until agreement was found.
Statistical Analyses
Before all meta-analyses, the standard mean differences and
sample sizes were checked for outliers. One outlier for the sample
size of nonpatients was found. Speciﬁcally, Smith et al. [7]
included 567 nonpatients. Studies with larger sample size are
given more weight as these are assumed to be more precise. In
such weighted estimation, studies with extremely large sample
size can deﬁne the entire meta-analysis if these are given accord-
ing weights [8]. Therefore, we recoded this study sample into the
highest nonextreme sample size of nonpatients (N = 246). Next,
we compared the results obtained with the original sample size to
those obtained with the recoded sample size. Because the results
remained almost unchanged, we present the data including the
original sample size.
One overall meta-analysis and three subanalyses by elicita-
tion method were performed. Before any of the analyses, data
within each of the retrieved studies were combined. If more than
one health state was valued in one single study, a meta-analysis
on the level of this primary study was performed. The differences
between patients and nonpatients were estimated for each health
state and were then combined into one estimator through meta-
analysis. This estimated mean difference was then used as esti-
mator for this study in the overall meta-analysis. In studies that
included more than one respondent group in either the patient or
the nonpatient group, estimations of both subsamples were
included. The sample size of the other group was divided by two,
and used twice to compare each of the subsamples. In studies
using more than one elicitation method, a meta-analysis on the
level of the primary study was performed.
Using the software Comprehensive Meta-Analysis (version
2.2.046) [9], the standard mean difference, Cohen’s d, and 95%
conﬁdence interval were estimated. We used Cohen’s d to control
for the difference in the numerical scales of TTO, SG, and VAS.
For each analysis by elicitation method, the unstandardized dif-
ference was estimated, instead of Cohen’s d.
The homogeneity of the sample was checked with the
Q-statistic [10]. If the sample of reports appeared to be hetero-
geneous, random effect models were used and moderator vari-
ables were analyzed to investigate if these could explain this
heterogeneity. The signiﬁcance of the six moderating effects was
checked using the Q-statistic. A signiﬁcant contrast means that
the moderator variable explains some of the heterogeneity
between the groups, but it does not necessarily imply that one
of the subsamples is homogeneous. For each subsample, we
again investigated the Q-statistic and Cohen’s d. The Duval and
Tweedie’s trim and ﬁll procedure [11] gave no indication for
publication bias in the overall meta-analysis, nor in the
subanalyses.
Results
The search yielded 36 studies of which 30 could be included in
the analyses. In 23 studies, participants rated more than
one health state, and in 13 studies, more than one elicitation
method was used. In these studies, meta-analyses on the level
of the primary study were performed. Information about both
the excluded and included studies can be found in Appendix B
at: http://www.ispor.org/Publications/value/ViHsupplementary/
ViH13i2_Peeters.asp.
Overall Meta-Analysis
From the included 30 studies, 40 mean differences in health state
valuations between patients and nonpatients, from now on
referred to as “estimators,” were extracted. The total set of
estimators was heterogeneous [Q(39) = 398.25, P < 0.01]. Using
the random effects model, the overall combined effect size for the
total set was signiﬁcant (Cohen’s d = 0.20, SD = 0.06, P < 0.01).
Patients gave higher valuations compared to nonpatients.
Figure 1 presents the standardized mean differences for each
study.
Two moderators showed a signiﬁcant contrast (Table 1).
Patients’ and nonpatients’ valuations were more distinct when no
label was provided than when it was. Furthermore, valuations
were more similar between groups when they both valued a
health state description than when patients valued their own
health. In terms of heterogeneity, the Q-statistic reveals that all
subsamples remain heterogeneous, except for the subsample of
studies without illness label. We want to emphasize that this
sample consisted of only three studies. Because this subsample
was homogeneous, the ﬁxed effect model was used to test the
group difference. For each subsample, the group difference is
reported as Cohen’s d.
Meta-Analysis of Studies by Estimation Method
The set of 25 TTO estimators was heterogeneous
[Q(24) = 263.85, P < 0.01]. The overall combined effect size
revealed a difference between the response groups (unstandard-
ized d = 0.05, SD = 0.02, P < 0 .05). Moderator analyses showed
a signiﬁcant contrast between studies with own health and
studies with a health state description [Q(1) = 5.93, P < 0.01].
When patients valued their own health (N = 3), their valuations
were different from those of nonpatients (unstandardized
d = 0.24, P < 0.01). When both groups valued a health state
description (N = 22), the valuations of the two groups were
similar (unstandardized d = 0.02, P > 0.05).
The set of 24 SG estimators was heterogeneous
[Q(23) = 116.36, P < 0.01]. There was no signiﬁcant difference
between response groups (unstandardized d = 0.01, SD = 0.01,
P > 0.05); therefore, search for moderator factors was not
performed.
The set of 22 VAS estimators was heterogeneous
[Q(21) = 189.47, P < 0.01]. A difference was seen between
respondent groups (unstandardized d = 0.04, SD = 0.02,
P < 0.01). Patients valued health states higher compared with
nonpatients. A signiﬁcant contrast was found between
professionals/proxies and members of the general public
[Q(1) = 9.53, P < 0.01]. Professionals/proxies (N = 6) did not
value health states different from patients (unstandardized
d = -0.04, P > 0.05), whereas members of the general public
(N = 16) gave lower valuations compared with patients
(unstandardized d = 0.07, P < 0.01).
Discussion
In this meta-analysis using 40 estimators from 30 studies, we
found a small to moderate difference in valuations between
patients and nonpatients. This ﬁnding contrasts with the ﬁndings
of Dolders et al. [2]. The exclusion of studies that used indirect
instruments is unlikely to have caused this, as Dolders et al. did
ﬁnd a difference in valuations between respondent groups in
studies using indirect instruments. A smaller number of included
studies is not an explanation either, becausewe included 29 studies
compared with only 11 by Dolders et al. From these 11 studies,
seven studies were selected for the current meta-analyses; of the
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remaining four studies included in Dolders et al., three were based
on indirect health state valuations, (the EQ-5D) and one study
valued health states worse than death and reported that the
majority of patients were unable to complete or understand the
measurement tasks. Newly published studies (N = 10) included in
our study may partly explain the difference. Finally, the difference
might be explained by the inclusion of multiple effect sizes by
Dolders et al. [2] which might have led to errors.
The results of the current study showed that states providing
an illness label were rated more similar by patients and nonpa-
Study name Std diff in means and 95% CI
Badia X., Herdman M., & Kind P. (1998)
Smith D.M., Sheriff R.L., Damschroder L., Loewenstein, G., & Ubel P.A. (2006)
Clarke A.E., Goldstein M.K., Michelson G.D., Garber A.M., & Lenert L.A. (1997) Chronic ill
Clarke A.E., Goldstein M.K., Michelson G.D., Garber A.M., & Lenert L.A. (1997) Gaucher disease
De Wit A.G., Busschbach J.J.V., & De Charro F.TH. (2000)
Suarez-Almazor M.E., & Conner-Spady B. (2001) prof
Suarez-Almazor M.E., & Conner-Spady B. (2001) public
Wells C.D., Murrill W.B., & Arguedas M.R. (2004)
Badia,X., Diaz-Prieto A., Rue M., & Patrick D.L. (1996)
Calhoun E.A., Fishman D.A., Lurain J.R., Welshman E.E., & Bennett C.L. (2004) public
Calhoun E.A., Fishman D.A., Lurain J.R., Welshman E.E., & Bennett C.L. (2004) prof
Korfage I.J., de Koning H.J., Habbeman D.F., Schröder F.H., & Essink-Bot ML. (2006)
Souchek J., Byrne M.M., Kelly P.A., O'Mally K., Richardson M., Pak C., Nelson H., & Suarez-Almazor M.E. (2005)
Ashby J., O'Hanlon M., & Buxton M.J. (1994) public
Ashby J., O'Hanlon M., & Buxton M.J. (1994) prof
Chen S., Shaheen A., & Garber A. (2008) public
Chen S., Shaheen A., & Garber A. (2008) prof
Cappelli M., Surh L., Humphreys L., Verma S., Logan D., Hunter A., & Allanson J. (2001)
Gabriel S.E., Kneeland T.S., Melton L.J., Moncur M.M., Ettinger B., & Tosteson A.N.A. (1999)
Goldberg J.H. (2006) public
Goldberg J.H. (2006) diabetes group
Postulart D. & Adang E.M.M. (2008)
Happich M. & von Lengerke T. (2005)
Hallan S., Asberg A., Indredavik B. & Wideroe T.E. (1999)
Boyd N.F., Sutherland H.J., Heasman K.Z., Trichler D.L. & Cummings B.J. (1990) public
Boyd N.F., Sutherland H.J., Heasman K.Z., Trichler D.L. & Cummings B.J. (1990) prof
Van der Donk J., et al. (1995) floor-of-the-mouth cancer/public
Van der Donk J., et al. (1995) floor-of-the-mouth cancer/prof
Van der Donk J., et al. (1995) laryngeal cancer/public
Van der Donk J., et al. (1995) laryngeal cancer/prof
Naraine V.S., Risebrough N.A., Oh P., Blanchette V.S., Lee S., Stain A-M., Hedden D., Teitel J.M., & Feldman B.M. (2002)
Cunningham S.J. & Hunt N.P. (2000)
Prosser L.A., Kuntz K.M., Bar-Or A. & Weinstein M.C. (2003)
Hayman J.A., Fairclough D.L., Harris J.R. & Weeks J.C. (1997)
Grann V.R., Jacobson J.S., Sundararajan V., Albert S.M., Troxel A.B. & Neugut A.I. (1999)
Stewart S.T., Lenert L., Bhatnagar V. & Kaplan R.M. (2005)
Molzahn A.E., Northcott H.C. & Dossetor J.B. (1997)
Hayman J.A., Kabeto M.U., Schipper M.J., Bennett J.E., Vicini F.A. & Pierce L.J. (2005)
Suarez-Almazor M.E., Conner-Spady B., Kendall C.J., Russell A. & Skeith K. (2001)
Sackett, D.L. & Torrance, G.W. (1978)
-2,00 0,00 1,00 2,00
Favours A Favours B
1
-1,00
Fugure 1 Mean standardized difference in Cohen’s d for each study and overall combined effect size.
Table 1 Moderator variables; contrast for each of the moderators
N† Cohen’ s d 95% CI Q Contrast*
Type of control group 2.54
Members of the general public 28 0.27** 0.15–0.38 259.88‡‡
Professionals/proxies 12 0.00 -0.30–0.30 131.21‡‡
Own /hypothetical 4.63‡
Scenario 34 0.14¶ 0.03–0.24 263.55‡‡
Own (patients valuing their own health) 6 0.67** 0.20–1.15 54.71‡‡
Type of scenario 0.28
Description 28 0.12¶ 0.00–0.24 240.70‡‡
EQ-5D 6 0.18 0.00–0.36 17.56‡‡
Illness Label 4.81‡
With label 37 0.18** 0.07–0.30 390.29‡‡
Without label 3 0.46** 0.24–0.68 1.87
Nonpatients actual/hypothetical 0.53
Actual (imagining the health of a patient) 2 -0.20 -1.31–0.91 9.75‡‡
Hypothetical 38 0.22** 0.10–0.33 388.22‡‡
Administration method 0.12
Computerized interview 7 0.27 -0.01–0.54 112.78‡‡
Interview without computer 30 0.21** 0.07–0.35 271.62‡‡
CI, conﬁdence interval; Q, heterogeneity statistic.
*Contrast between sets of studies, in Q.
†The total N does sometimes not add up to 41 due to missing data.
‡Contrast for the moderator variable is signiﬁcant P < 0.05.
¶Effect size of the subsample is signiﬁcant P < 0.05.
**Effect size of the subsample is signiﬁcant P < 0.01.
‡‡Subsample is heterogeneous P < 0.01.
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tients than states not providing an illness label. Possibly, healthy
subjects, like patients, will not use the whole utility continuum
for labeled health states [12]. Another contrast was shown
between studies in which patients valued their own health and
studies in which patients valued a health state description. Valu-
ations were more similar between groups when they both valued
a description. This might be explained by a so-called loss aver-
sion, patients giving higher valuations when they “own” a health
state [13]. Initially, in three studies, the judges disagreed on this
moderator variable, but after reading through the studies again,
agreement was easily found. The disagreement was in two studies
due to poor reporting and in one study due to a poor deﬁnition.
Only in the meta-analysis including studies for the VAS was
an effect for the type of nonpatient group found. Valuations of
professionals/proxies were more similar to those of patients than
valuations of the general public, probably because of their expe-
rience with patients. In future meta-analyses, it may be worth-
while to start off by stratifying by both disease label and type of
health state valued by patients (own health vs. scenarios), as
these had moderating effects.
Despite the use of several moderator factors, all samples
remained heterogeneous, except for three studies without illness
label. Different explanations may be given for this heterogeneity.
First, a great diversity was seen between the type and severity of
the health states. As shown by Insinga and Fryback [14], the
difference between valuations given by different respondent
groups may depend on the severity of the health state. Second,
patients as well as members of the general public differ in the
extent of their experience with different health states, which
creates heterogeneous groups [15]. Unfortunately, we were not
able to control for the differences in experience and the choice of
the particular health states.
In this study, multiple signiﬁcance tests were carried out,
which might have led to multiplicity. Using Bonferroni correc-
tion, the main results of the elicitation subsamples remained the
same. Correcting the moderator variables in the overall meta-
analysis and in the meta-analysis of studies by elicitation method,
nonsigniﬁcant contrasts for all samples were found. However, it
has been argued that tests performed to investigate heterogeneity
should not be adjusted for multiple testing [16].
Given our results, future studies should take the impact of
respondent group into account. Which respondent group should
assign health state valuations depends on the research question of
the study. For cost-utility analysis, the implications of our ﬁnd-
ings can be best illustrated using the unstandardized differences.
Mean unstandardized difference in studies using the TTO or the
VAS was 0.05 and 0.04 with a 95% conﬁdence interval of
0.01–0.08 for the TTO and 0.01–0.07 for the VAS. The inﬂuence
of such a difference on a cost-utility ratio depends on other
characteristics included in the analysis, for example the period
for which the effect of treatment lasts. In studies using the SG, no
effect of respondent group was seen, probably due to ceiling
effects caused by risk aversion [13].
Given the small sample sizes and different ﬁndings between
the meta-analyses, we feel that we cannot claim implications for
the ﬁndings of the moderator analyses. These results should be
corroborated in future research.
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